News
Endeavor
to Achieve Our Goals
News
to Achieve Our Goals
September 16, 2021
January 7, 2021
September 24, 2021
January 7, 2021
January 7, 2021
January 7, 2021
September 9, 2022
© 2023 – Endeavor Biomedicines | Privacy Notice | Terms of Use
Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
/in news, Press ReleaseSeptember 6, 2023
Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
/in news, Press ReleaseMay 31, 2022
Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
/in news, Press ReleaseMay 25, 2022
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
/in news, Press ReleaseFebruary 7, 2022
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
/in news, Press ReleaseFebruary 07, 2022
Endeavor Biomedicines doses first patient in phase 2 clinical trial of Taladegib (ENV-101) for idiopathic pulmonary fibrosis; appoints chief medical officer
/in news, Press ReleaseSeptember 22, 2021
Endeavor Biomedicines Licenses Ulk1/2 Inhibitor Program From Salk Institute And Sanford Burnham Prebys To Broaden Its Precision Oncology Pipeline
/in news, Press ReleaseSeptember 16, 2021
Endeavor Biomedicines Launches With $62 Million Series A Financing And Mission To Reverse The Course Of Devastating Pulmonary Disease
/in news, Press ReleaseJanuary 7, 2021